妊娠期与孕前糖尿病筛查在妊娠早期的变化及围产结局
该研究纳入2018至2022年间分娩的221,068例无显性糖尿病的活产患者,采用中断时间序列分析评估减少24周前妊娠期糖尿病筛查并增加早期糖化血红蛋白检测这一举措与围产并发症的关联。结果显示早期GDM筛查率从31.1%降至4.3%,Hb A1C检测率从12.3%升至35.2%,但复合围产结局无变化。
要点
- 早期GDM筛查率从T1的31.1%降至T3的4.3%,Hb A1C检测率从12.3%升至35.2%。
- 复合围产结局发生率T1为43.1%、T2为44.2%、T3为45.2%,无显著变化。
- 中断时间序列分析显示各时期复合结局风险均无显著变化。
核心结论
- 减少早期GDM筛查并增加早期Hb A1C检测未影响围产结局。
研究设计与样本
- 纳入2018年至2022年间分娩的221,068例活产且无显性糖尿病的患者。
- 采用中断时间序列分析,按暴露程度分为T1(2018年1月1日至2020年3月31日,未暴露)、T2(2020年4月1日至12月31日,部分暴露)、T3(2021年1月1日至2022年12月31日,完全暴露)。
主要发现
- 早期GDM筛查率T1为31.1%、T2为20.6%、T3为4.3%(T3 vs T1的标准化均数差[SMD]为-0.75)。
- Hb A1C检测率从T1的12.3%升至T3的35.2%(SMD T3 vs T1为0.56)。
- 复合主要结局发生率T1为43.1%、T2为44.2%、T3为45.2%(SMD T3 vs T1为0.04)。
- 校正协变量后,复合结局风险在T1的每4周百分比变化为0.06(95%CI -0.01至0.13),T2为0.02(95%CI -0.21至0.25),T3为-0.02(95%CI -0.26至0.23)。
关键数值与推荐
- 复合主要结局包括大于胎龄儿出生体重、剖宫产、子痫前期、严重孕产妇并发症、早产、肩难产、新生儿低血糖和新生儿重症监护病房入住。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate an initiative to decrease gestational diabetes (GDM) screening rates before 24 weeks of gestation and to increase early-pregnancy hemoglobin A 1C (Hb A 1C ) testing for undiagnosed pregestational diabetes and the association of this change with perinatal complications. METHODS: All patients with live births and without overt diabetes who delivered between 2018 and 2022 were included. We performed an interrupted time series analysis to examine perinatal outcomes associated with the recommended changes. To reflect the level of exposure to recommended changes that started April 2020, delivery dates were categorized into three time periods: T1, unexposed (January 1, 2018-March 31, 2020); T2, partially exposed (April 1-December 31, 2020); and T3, fully exposed (January 1, 2021-December 31, 2022). The primary outcome was a composite including large-for-gestational-age birth weight, cesarean delivery, preeclampsia, severe maternal morbidity, preterm birth, shoulder dystocia, neonatal hypoglycemia, and neonatal intensive care unit admission. RESULTS: Among 221,068 delivering individuals, early GDM screening rates decreased from 31.1% in T1 to 20.6% in T2 and 4.3% in T3 (standardized mean difference [SMD] T3 vs T1, -0.75), and Hb A 1C testing increased from 12.3% to 23-35.2% (SMD T3 vs T1, 0.56). There was no change in the prevalence of the composite primary outcome: 43.1% in T1, 44.2% in T2, and 45.2% in T3 (SMD T3 vs T1, 0.04). Interrupted time series analysis adjusted for covariates showed no change in risk of the composite outcome during T1 (percent change/4 weeks, 0.06 [95% CI, -0.01 to 0.13]), T2 (0.02 [95% CI, -0.21 to 0.25]), or T3 (-0.02 [95% CI, -0.26 to 0.23]). CONCLUSION: A decrease in early GDM screening accompanied by increased early Hb A 1C testing did not influence perinatal outcomes.
引用
- Greenberg M, Zhu Y, Shan J, et al. Gestational and Pregestational Diabetes Screening Changes in Early Pregnancy and Perinatal Outcomes. Obstet Gynecol. 2025. PMID: 41100860. doi:10.1097/AOG.0000000000006090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。